English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Dendritic cells ( DC s) are potent and specialized antigen presenting cells, which play a crucial role in initiating and amplifying both the innate and adaptive immune responses against cancer. Tumor cells can escape from immune attack by secreting suppressive cytokines that solely or cooperatively impair the immune function of  DC s. However, the underlying mechanisms are not fully defined. Vascular endothelial growth factor ( VEGF ) has been identified as a major cytokine in the tumor microenvironment. To elucidate the effects of  VEGF  on the motility and immune function of mature  DC s ( mDC s), the cells were treated with 50 ng/ mL VEGF  and investigated by proteomics and molecular biological technologies. The results showed that  VEGF  can impair the migration capacity and immune function of  mDC s through the RhoA‐cofilin1 pathway mediated by the  VEGF  receptor 2, suggesting impaired motility of  mDC s by  VEGF  is one of the aspects of immune escape mechanisms of tumors. It is clinically important to understand the biological behavior of  DC s and the immune escape mechanisms of tumor as well as how to improve the efficiency of antitumor therapy based on DCs.

cancer science

Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2‐RhoA‐cofilin1 pathway